Troy Taylor

Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component

Reducing cell intrinsic immunity to mRNA vaccine alters adaptive immune responses in mice

No evidence for basigin/CD147 as a direct SARS-CoV-2 spike binding receptor

Computationally designed sensors detect endogenous Ras activity and signaling effectors at subcellular resolution

Systemic IL-15, IFN-γ, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients

Mechanisms of SARS-CoV-2 entry into cells

Crystallographic, thermodynamic, and molecular modeling studies of the mode of binding of oligosaccharides to the potent antiviral protein griffithsin

Monomerization of Viral Entry Inhibitor Griffithsin Elucidates the Relationship between Multivalent Binding to Carbohydrates and anti-HIV Activity

Structural insights into the specific anti-HIV property of actinohivin: structure of its complex with the α(1–2)mannobiose moiety of gp120

HIV-1 Neutralization Profile and Plant-Based Recombinant Expression of Actinohivin, an Env Glycan-Specific Lectin Devoid of T-Cell Mitogenic Activity

An Intranasal Virus-Like Particle Vaccine Broadly Protects Mice from Multiple Subtypes of Influenza A Virus

A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes

Recombinant production of anti-HIV protein, griffithsin, by auto-induction in a fermentor culture

Purify First: Rapid expression and purification of proteins from XMRV

Optimizing high-yield production of SARS-CoV-2 soluble spike trimers for serology assays

KRAS interaction with RAF1 RAS-binding domain and cysteine-rich domain provides insights into RAS-mediated RAF activation